Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $14.35 in the prior trading day, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed at $14.62, up 1.88%. In other words, the price has increased by $1.88 from its previous closing price. On the day, 1.57 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ACAD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.51. For the most recent quarter (mrq), Quick Ratio is recorded 2.32 and its Current Ratio is at 2.38. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Deutsche Bank on February 11, 2025, initiated with a Hold rating and assigned the stock a target price of $22.
On January 03, 2025, Guggenheim Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $23 to $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 08 ’25 when Schneyer Mark C. sold 2,708 shares for $14.82 per share. The transaction valued at 40,133 led to the insider holds 59,456 shares of the business.
Kihara James sold 1,028 shares of ACAD for $15,235 on Apr 08 ’25. The PRINCIPAL ACCOUNTING OFFICER now owns 22,257 shares after completing the transaction at $14.82 per share. On Mar 26 ’25, another insider, Kihara James, who serves as the PRINCIPAL ACCOUNTING OFFICER of the company, sold 1,095 shares for $17.05 each. As a result, the insider received 18,670 and left with 21,275 shares of the company.
Valuation Measures:
As of this moment, Acadia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 10.75, and their Forward P/E ratio for the next fiscal year is 15.42. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 8.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.55 while its Price-to-Book (P/B) ratio in mrq is 3.33.
Stock Price History:
Over the past 52 weeks, ACAD has reached a high of $20.68, while it has fallen to a 52-week low of $13.40. The 50-Day Moving Average of the stock is -14.59%, while the 200-Day Moving Average is calculated to be -13.14%.
Shares Statistics:
A total of 166.71M shares are outstanding, with a floating share count of 165.49M. Insiders hold about 0.78% of the company’s shares, while institutions hold 99.22% stake in the company.
